Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

456.04 +6.48 (+1.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?
Alnylam stock fell after a strong Q3 with $2.90 EPS and $1.25 billion revenue, a subpoena disclosure, and raised 2025 sales guidance to $3.6 billion–$3.8 billion. 
Via Benzinga
Topics Law Enforcement
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Stock Dips Despite Blowout Q3 2025 Earnings
Alnylam's Q3 2025 earnings crushed estimates with a $2.90 EPS and 149% revenue growth, driven by AMVUTTRA, despite a pre-market stock dip. 
Via Chartmill
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
The company easily beat third-quarter expectations and issued guidance that widely topped forecasts. 
Via Investor's Business Daily
Uncovering Potential: Alnylam Pharmaceuticals's Earnings Preview
 
Via Benzinga
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. 
Via Benzinga
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome... 
Via Benzinga
Topics Economy
Earnings Scheduled For October 30, 2025
 
Via Benzinga
Peering Into Alnylam Pharmaceuticals Inc's Recent Short Interest
 
Via Benzinga
$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the potential catalysts driving attention. 
Via Benzinga
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout
Alnylam Pharmaceuticals (ALNY) presents a strong technical breakout setup with a high rating for both trend momentum and consolidation quality. 
Via Chartmill
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
 
Via Benzinga
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam... 
Via Benzinga
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary... 
Via Benzinga
Beyond The Numbers: 28 Analysts Discuss Alnylam Pharmaceuticals Stock
 
Via Benzinga
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
 
Via Benzinga
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
 
Via Benzinga
A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics
 
Via Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
 
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
 
Via Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
 
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
 
Via Benzinga
Demystifying Alnylam Pharmaceuticals: Insights From 19 Analyst Reviews
 
Via Benzinga
This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Reddit, Wingstop, And Generac Are Among Top 10 Large Cap Gainers Last Week (July 28-August 1): Are The Others In Your Portfolio?
Reddit, Wingstop, and Generac led large-cap gains last week on strong Q2 results and upbeat guidance across multiple sectors. 
Via Benzinga
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
Alnylam sees strong Amvuttra uptake in ATTR-CM with $150 million revenue boost; analysts hike price targets following FDA approval and launch momentum. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.